HARVARD BIOSCIENCE INC (HBIO) Stock Overview
NASDAQ:HBIO - US4169061052 - Common Stock
HBIO Key Statistics, Chart & Performance
The current stock price of HBIO is 0.489 USD. In the past month the price decreased by -13.41%. In the past year, price decreased by -83.65%.
HBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 22.84 | 188.80B | ||
| DHR | DANAHER CORP | 28.13 | 151.66B | ||
| A | AGILENT TECHNOLOGIES INC | 22.52 | 34.55B | ||
| IQV | IQVIA HOLDINGS INC | 16.67 | 32.50B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 32.31 | 27.22B | ||
| WAT | WATERS CORP | 24.71 | 17.99B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 35.61 | 17.82B | ||
| ILMN | ILLUMINA INC | 24.47 | 15.65B | ||
| TEM | TEMPUS AI INC | N/A | 13.99B | ||
| ICLR | ICON PLC | 13.29 | 13.67B | ||
| MEDP | MEDPACE HOLDINGS INC | 34.47 | 13.02B | ||
| RVTY | REVVITY INC | 19.25 | 10.93B |
Related stock screener links
About HBIO
Company Profile
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 330 full-time employees. The company went IPO on 2013-10-21. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
Company Info
HARVARD BIOSCIENCE INC
84 October Hill Rd
Holliston MASSACHUSETTS 01746 US
CEO: James Green
Employees: 343
Phone: 15088938999
HARVARD BIOSCIENCE INC / HBIO FAQ
What is the stock price of HARVARD BIOSCIENCE INC today?
The current stock price of HBIO is 0.489 USD. The price increased by 2.71% in the last trading session.
What is the ticker symbol for HARVARD BIOSCIENCE INC stock?
The exchange symbol of HARVARD BIOSCIENCE INC is HBIO and it is listed on the Nasdaq exchange.
On which exchange is HBIO stock listed?
HBIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HARVARD BIOSCIENCE INC stock?
8 analysts have analysed HBIO and the average price target is 3.06 USD. This implies a price increase of 525.77% is expected in the next year compared to the current price of 0.489. Check the HARVARD BIOSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HARVARD BIOSCIENCE INC worth?
HARVARD BIOSCIENCE INC (HBIO) has a market capitalization of 21.78M USD. This makes HBIO a Nano Cap stock.
How many employees does HARVARD BIOSCIENCE INC have?
HARVARD BIOSCIENCE INC (HBIO) currently has 343 employees.
What are the support and resistance levels for HARVARD BIOSCIENCE INC (HBIO) stock?
HARVARD BIOSCIENCE INC (HBIO) has a support level at 0.48 and a resistance level at 0.51. Check the full technical report for a detailed analysis of HBIO support and resistance levels.
Is HARVARD BIOSCIENCE INC (HBIO) expected to grow?
The Revenue of HARVARD BIOSCIENCE INC (HBIO) is expected to decline by -8.8% in the next year. Check the estimates tab for more information on the HBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HARVARD BIOSCIENCE INC (HBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HBIO, evaluating the profitability, health, valuation and growth aspects
- HARVARD BIOSCIENCE INC (HBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HARVARD BIOSCIENCE INC (HBIO) Sales and EPS estimates to see what analysts future expectations are.
- HARVARD BIOSCIENCE INC (HBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HARVARD BIOSCIENCE INC (HBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- HARVARD BIOSCIENCE INC (HBIO) Stock Chart to make your own analysis
- HARVARD BIOSCIENCE INC (HBIO) Latest news and press-releases to stay up to date.
Does HARVARD BIOSCIENCE INC (HBIO) stock pay dividends?
HBIO does not pay a dividend.
When does HARVARD BIOSCIENCE INC (HBIO) report earnings?
HARVARD BIOSCIENCE INC (HBIO) will report earnings on 2025-11-05, before the market open.
What is the Price/Earnings (PE) ratio of HARVARD BIOSCIENCE INC (HBIO)?
The PE ratio for HARVARD BIOSCIENCE INC (HBIO) is 24.45. This is based on the reported non-GAAP earnings per share of 0.02 and the current share price of 0.489 USD. Check the full fundamental report for a full analysis of the valuation metrics for HBIO.
What is the Short Interest ratio of HARVARD BIOSCIENCE INC (HBIO) stock?
The outstanding short interest for HARVARD BIOSCIENCE INC (HBIO) is 3.33% of its float. Check the ownership tab for more information on the HBIO short interest.
HBIO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to HBIO. When comparing the yearly performance of all stocks, HBIO is a bad performer in the overall market: 89.65% of all stocks are doing better.
HBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HBIO. HBIO may be in some trouble as it scores bad on both profitability and health.
HBIO Financial Highlights
Over the last trailing twelve months HBIO reported a non-GAAP Earnings per Share(EPS) of 0.02. The EPS decreased by -71.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.67% | ||
| ROE | -364.88% | ||
| Debt/Equity | 0 |
HBIO Forecast & Estimates
8 analysts have analysed HBIO and the average price target is 3.06 USD. This implies a price increase of 525.77% is expected in the next year compared to the current price of 0.489.
For the next year, analysts expect an EPS growth of -57.5% and a revenue growth -8.8% for HBIO